var data={"title":"Amifostine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amifostine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5607?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amifostine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amifostine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amifostine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amifostine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132861\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ethyol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132862\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ethyol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132892\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Chemoprotective Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132865\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential. Antiemetic medication, including dexamethasone (20 mg IV when used for cisplatin-induced renal toxicity) and a serotonin 5-HT<sub>3</sub> receptor antagonist, is recommended prior to and in conjunction with amifostine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal toxicity (cisplatin-induced):</b> IV: 910 mg/m<sup>2</sup> once daily over 15 minutes 30 minutes prior to cytotoxic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For 910 mg/m<sup>2</sup> doses, the manufacturer suggests the following blood pressure-based adjustment schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>The infusion of amifostine should be interrupted if the systolic blood pressure decreases significantly from baseline, as defined below:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease of 20 mm Hg if baseline systolic blood pressure &lt;100</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease of 25 mm Hg if baseline systolic blood pressure 100 to 119</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease of 30 mm Hg if baseline systolic blood pressure 120 to 139</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease of 40 mm Hg if baseline systolic blood pressure 140 to 179</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Decrease of 50 mm Hg if baseline systolic blood pressure &ge;180</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If blood pressure returns to normal within 5 minutes (assisted by fluid administration and postural management) and the patient is asymptomatic, the infusion may be restarted so that the full dose of amifostine may be administered. If the full dose of amifostine cannot be administered, the dose of amifostine for subsequent cycles should be 740 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Xerostomia due to radiation therapy for head and neck cancer: </b>IV: 200 mg/m<sup>2</sup> over 3 minutes once daily 15 to 30 minutes prior to radiation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Radiation proctitis in rectal cancer, prevention (off-label use):</b> IV: 340 mg/m<sup>2</sup> once daily prior to radiation therapy (Lalla 2014; Peterson 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132866\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671498\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671499\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48952936\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cutaneous reactions or mucosal lesions appearing outside of the injection site or radiation port: Discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bullous, edematous or erythematous lesions on the palms or soles: Discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute allergic reaction: Discontinue permanently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132843\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ethyol: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132828\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132846\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea/vomiting (Dupuis 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer over 3 minutes (15 to 30 minutes prior to radiation therapy) or over 15 minutes (30 minutes prior to cisplatin); administration as a longer infusion is associated with a higher incidence of side effects. Patients should be adequately hydrated and kept in supine position during infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132844\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal toxicity (cisplatin-induced): </b>Reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Xerostomia due to radiation therapy for head and neck cancer:</b> Reduce the incidence of moderate-to-severe xerostomia in patients undergoing postoperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: The clinical data do not suggest the efficacy of cisplatin-based chemotherapy or radiation therapy for the approved indications is altered by amifostine. Data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings is limited. Do not administer amifostine in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, unless within the context of a clinical study.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720679\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Radiation proctitis in patients with rectal cancer (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132900\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ethyol may be confused with ethanol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132835\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (ovarian cancer: 61% to 62%; head and neck cancer: 15%; generally transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (ovarian cancer: 96%; head and neck cancer: 53%), severe nausea and vomiting (ovarian cancer: 19%; head and neck cancer: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Endocrine &amp; metabolic: Hypocalcemia (head and neck cancer: 1%; clinically significant)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia, chest pain, extrasystoles, flushing, ischemic heart disease, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, dizziness, drowsiness, malaise, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema multiforme, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea, hiccups</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (includes bruising at injection site, erythema at injection site, inflammation at injection site, injection site pruritus, pain at injection site, rash at injection site, swelling at injection site, urticaria at injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, dyspnea, hypoxia, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, atrial fibrillation, atrial flutter, cardiac arrhythmia, DRESS syndrome, hypersensitivity reaction (includes chest discomfort, laryngeal edema, pruritus, rigors, urticaria), myocardial infarction, renal failure, seizure, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, toxic epidermal necrolysis, transient hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132849\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amifostine, aminothiol compounds, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132832\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Serious cutaneous reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxicoderma, exfoliative dermatitis, and drug reaction with biopsy-proven eosinophilia and system symptoms (DRESS) have been reported with amifostine. May be delayed, developing up to weeks after treatment initiation. Cutaneous reactions have been reported more frequently when used as a radioprotectant. Evaluate for dermatologic reactions prior to each dose, during therapy and after treatment discontinuation. Discontinue treatment for severe/serious cutaneous reactions or mucosal lesions that appear outside of the radiation port and for bullous, edematous, or erythematous lesions on the palms or soles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Rare hypersensitivity reactions, including anaphylaxis and allergic reaction, have been reported. Discontinue if severe acute allergic reaction occurs; do not rechallenge. Medications for the treatment of hypersensitivity reactions should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Reports of clinically-relevant hypocalcemia are rare, but serum calcium levels should be monitored in patients at risk of hypocalcemia, such as those with nephrotic syndrome, or patients receiving multiple amifostine doses. May require calcium supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Hypotension may occur during or shortly after infusion. Short term (reversible) syncope (loss of consciousness) has been rarely reported. Patients who are hypotensive or dehydrated should not receive amifostine. Adequately hydrate prior to treatment and keep in a supine position during the infusion. Monitor blood pressure every 5 minutes during the infusion. If hypotension requiring interruption of therapy occurs, patients should be placed in the Trendelenburg position and given an infusion of normal saline using a separate IV line; subsequent infusions may require a dose reduction. Infusions &gt;15 minutes are associated with a higher incidence of adverse effects. Interrupt antihypertensive therapy for 24 hours before treatment; patients who cannot safely stop their antihypertensives 24 hours before should not receive amifostine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nausea/vomiting: Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential (Dupuis 2011). The incidence of nausea and vomiting is higher in patients receiving amifostine compared to chemotherapy alone. Antiemetic medications, including dexamethasone 20 mg IV and a serotonin 5-HT<sub>3</sub> receptor antagonist, should be administered prior to and in conjunction with amifostine. Use with caution in patients for whom the adverse effects of nausea/vomiting may have serious adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or whom the adverse effects of hypotension may have serious adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: According to the manufacturer, amifostine should not be used (in patients receiving chemotherapy for malignancies other than ovarian cancer) where chemotherapy is expected to provide significant survival benefit or in patients receiving definitive radiotherapy, unless within the context of a clinical trial. The American Society of Clinical Oncology (ASCO) has published guidelines for the use of protectants for chemotherapy and radiation (Hensley 2009). According to the ASCO guidelines, amifostine may be considered for prevention of nephrotoxicity in patients receiving cisplatin-based therapy. While amifostine may be considered to reduce the incidence of grade 3 or 4 neutropenia associated with chemotherapy, the guidelines suggest that alternative strategies (eg, growth factors) may be utilized in this situation. The guidelines recommend against the use of amifostine to reduce the incidence of thrombocytopenia associated with chemotherapy or radiation therapy. Data is insufficient to recommend amifostine for prevention of neurotoxicity or ototoxicity associated with platinum-based chemotherapy, for prevention of neurotoxicity associated with paclitaxel, for prevention of radiation therapy-induced mucositis associated with head and neck cancer, or for prevention of esophagitis due to chemotherapy in patients with non-small cell lung cancer. Additionally, amifostine may be considered to decrease the incidence of acute and late xerostomia in patients undergoing radiation therapy alone (for head and neck cancer); however, the guidelines do not support the use of amifostine in patients with head and neck cancer receiving concurrent platinum-based chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298731\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132837\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8533&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930085\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930087\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if amifostine is present in breast milk. Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during amifostine treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132841\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (monitor every 5 minutes during the infusion and after administration if clinically indicated); serum calcium levels (in patients at risk for hypocalcemia). Evaluate for cutaneous reactions prior to each dose, during therapy, and after treatment discontinuation. Monitor hydration status.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132831\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically-active free thiol metabolite. The free thiol is available to bind to, and detoxify, reactive metabolites of cisplatin; and can also act as a scavenger of free radicals that may be generated (by cisplatin or radiation therapy) in tissues.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132848\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic dephosphorylation to two metabolites (active-free thiol and disulfide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children: 9.3 minutes (Fouladi 2001); Adults: ~8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (minimal; as amifostine and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322980\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ethyol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1,275.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132852\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amifos (PK);</li>\n      <li>Amiphos (IN);</li>\n      <li>Erifostine (AR);</li>\n      <li>Ethyol (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KR, LU, MX, NI, NL, NZ, PA, PE, PH, PL, PT, QA, SE, SV, TR, TW, UY, VE);</li>\n      <li>Tian Di Da (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brizel DM, Wasserman TH, Henke M, et al, &ldquo;Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer,&rdquo; <i>J Clin Oncol</i>, 2000, 18(19): 3339-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/11013273/pubmed\" target=\"_blank\" id=\"11013273\">11013273</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ethyol (amifostine) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fouladi M, Stempak D, Gammon J, et al, &ldquo;Phase I Trial of a Twice-Daily Regimen of Amifostine With Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children With Refractory Carcinoma,&rdquo; <i>Cancer</i>, 2001, 92(4):914-23.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo; <i>J Clin Oncol</i>, 2009, 27(1): 127-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/19018081/pubmed\" target=\"_blank\" id=\"19018081\">19018081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2014;120(10):1453-1461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/24615748/pubmed\" target=\"_blank\" id=\"24615748\">24615748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. <i>Ann Oncol.</i> 2015;26 Suppl 5:v139-151.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-drug-information/abstract-text/26142468/pubmed\" target=\"_blank\" id=\"26142468\">26142468</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8533 Version 117.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132861\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132862\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F132892\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F132865\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F132866\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671498\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671499\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F48952936\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132843\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F132828\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F132846\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F132844\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720679\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132900\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132835\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132849\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132832\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298731\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132837\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2930085\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2930087\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F132841\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132831\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F132848\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322980\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132852\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8533|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amifostine-patient-drug-information\" class=\"drug drug_patient\">Amifostine: Patient drug information</a></li><li><a href=\"topic.htm?path=amifostine-pediatric-drug-information\" class=\"drug drug_pediatric\">Amifostine: Pediatric drug information</a></li></ul></div></div>","javascript":null}